anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Venoarterial extracorporeal membrane oxygenation (VA ECMO) has become a standard of care for severe cardiogenic shock, refractory cardiac arrest and related impending multiorgan failure. The widespread clinical use of this complex temporary circulatory support modality is still contrasted by a lack of formal scientific evidence in the current literature. This might at least in part be attributable to VA ECMO related complications, which may significantly impact on clinical outcome. In order to limit adverse effects of VA ECMO as much as possible an indepth understanding of the complex physiology during extracorporeally supported cardiogenic shock states is critically important. This review covers all relevant physiological aspects of VA ECMO interacting with the human body in detail. This, to provide a solid basis for health care professionals involved in the daily management of patients supported with VA ECMO and suffering from cardiogenic shock or cardiac arrest and impending multiorgan failure for the best possible care.
A patient platform for patient engagement and treatment compliance is disclosed. In an example, a processor is configured to obtain medical information from a patient for engagement and treatment compliance tracking. To obtain the medical information, the processor causes a user interface to be displayed with fields to be populated with medical information. After receiving a selection of a data field, the processor provides an option to enter medical information from an image. If the option is selected, the processor receives a recorded image of a medical device or a screen of a medical device, extracts text from the image, enables a selection of at least a portion of the text from the image, and writes the selected text from the image into the data field of the user interface as the medical information. The processor transmits the medical information to a patient medical record stored in a clinician database.
PURPOSE:A cosmetic having high cleansing effect, and good protecting action on the skin, containing a water extracted solution of a koji. CONSTITUTION:A mold having high protease activity, e.g., yellow koji mold such as Aspergillus oryzae, black koji mold such as Aspergillus niger, etc., fungus belonging to the genus Rhizopus, Penicillium, etc. is grown in thermally modified wheat, rice, soybean, maize, gluten, etc. to give a koji, which is extracted with 5-15times as much as water, and sterilized by a means such as sterile filtration, gas sterilization, etc. not to deactivate enzymes. 1-10wt% of the prepared water extracted solution of a koji is added to a cosmetic, especially a cleansing cosmetic. The water extracted solution of a koji has high activity of a protease system, contains various kinds of enzymes, and the water extracted solution especially obtained by growing the yellow koji mold has extremely high activity of a protease system.
Participants will receive Alcohol-containing Essential Oil (AEO) containing mouth rinse (Listerine Cool Mint, marketed) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
This study retrospectively analyzed the clinical efficacy of Uncut Roux-en-Y and Billroth II anastomoses in gastrointestinal reconstruction following laparoscopic D2 radical gastrectomy for distal gastric cancer. The primary objective was to compare the postoperative outcomes, including quality of life and complication rates, between the 2 surgical techniques. One hundred patients diagnosed with distal gastric cancer were enrolled between June 2020 and May 2023. Patients underwent laparoscopic D2 gastrectomy and were categorized into either the Uncut Roux-en-Y or Billroth II anastomosis groups based on the technique used for gastrointestinal reconstruction. The inclusion and exclusion criteria were strictly followed. Surgical parameters, quality of life assessed using the Visick grading index, and postoperative complications were also evaluated. Statistical analyses were performed using SPSS version 27.0. The groups were comparable in terms of demographic and baseline clinical parameters. The Uncut Roux-en-Y group had a significantly longer duration of surgery (P < .001). However, there were no statistically significant differences in other surgical parameters. According to the Visick grading index, patients in the Uncut Roux-en-Y group reported a significantly better quality of life than those in the Billroth II group (P < .05). Additionally, Uncut Roux-en-Y was associated with a significantly lower incidence of dumping syndrome and bile reflux (P < .05). Although Uncut Roux-en-Y anastomosis requires longer surgical time, it offers significant advantages in terms of postoperative quality of life and reduced rates of dumping syndrome and bile reflux. Our findings suggest that Uncut Roux-en-Y may be a superior option for gastrointestinal reconstruction after laparoscopic D2 gastrectomy for distal gastric cancer.
Breast cancer (BC) is the commonest cancer, affecting 1.4 million women per year of whom a third die from the disease. There is an urgent need for new approaches to BC prevention. Progesterone is a hormone that is produced naturally from a woman's ovaries during each menstrual cycle and is often used in hormone replacement therapy (HRT) after the menopause. When used in HRT progesterone increases the risk of BC and BC death. In experiments in mice and rats progesterone has been shown to increase the growth of the normal mammary gland (the rodent breast). When human breast tissue is grown in the laboratory it also grows in response to progesterone. In particular progesterone has been shown to increase the growth of particular cells called stem cells which survive for a long time in the breast. It is thought that the exposure of these stem cells to progesterone over many years is the reason that women whose periods start early and finish late or those who do not have a pregnancy to interrupt their menstrual cycles and those that take HRT all have an increased risk of BC.

In this project the investigators will use a drug that blocks the effects of progesterone called ulipristal acetate (UA, EsmyaTM) that is currently licenced in the treatment of fibroids of the uterus. When used to treat fibroids UA is very well tolerated with no increase in side effects compared to a placebo tablet. 30 women at increased risk of BC will be recruited and have magnetic resonance imaging (MRI) scan and mammogram followed by a biopsy of one breast. After 3 months of UA treatment the MRI will be repeated along with a biopsy from the other breast. The effects of UA on many different cell types in the biopsies, including the stem cells and also the tissues like collagen that support them will be examined in detail. The effects of UA treatment on gene and protein expression in the breast tissue will also be examined. The goal is to identify which women will be sensitive or resistant to UA as a BC prevention treatment. In addition changes in the MRI scans with UA treatment will be examined using several different analysis techniques to try and identify who will likely benefit from UA treatment in the future without the need for biopsies.
A hygiene composition comprising 4-30% w/w of a solute, wherein the solute comprises 0-3% preservative and 0-25% antimicrobial agent, and 70-96% water and wherein the composition is dispensable using an apparatus and the solute is engineered to be mixed and activated upon contact with the water in the apparatus. The solute may be a solid or a liquid. The preservative may be sodium benzoate and the antimicrobial may be sodium anisate, a potassium alum, a Leuconostoc/radish root ferment filtrate, or zinc oxide. The composition may comprise 0-25% texturizing agent and 0-10% thickening agent. The texturizing agent may be a trilaurin, a diatomaceous earth, a Maranta arundinacea (arrowroot) or an Oryza sativa (rice) starch. The thickening agent may be xanthan gum, sclerotium gum, an inulin or an Aloe barbadensis leaf juice. The solution may further comprise an emollient, an anti-inflammatory, an astringent, a viscosity modifier, an absorbent, a conditioning agent, a probiotic complex, a prebiotic complex or an aroma compound. The composition may be at least one of a cosmetic product, a cleaning product, a bleaching product, a polishing product or a medication. The apparatus may be a spray pump bottle.
Participant in the intervention arm will receive immersive virtual reality intervention in the form of VR box (Shinecon 6.0 VR Box Virtual Reality Glasses with headphones). SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) which attached to the head of cancer patient during chemotherapy, by displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical audio instruments (non-copyright).
PURPOSE: To obtain the subject new compound useful as an antibacterial agent against Gram-positive bacteria, Gram-negative bacteria, esp. resistant bacteria such as multiple drug-resistant MRSA and drug-resistant Pseudomonas aeruginosa. CONSTITUTION: This new compound is expressed by formula I (R1 is H or a lower alkyl such as methyl; R2 is a negative electric charge, H, or an ester residue such as a lower alkanoyloxy or a lower alkyl group; A ring is an unsaturated N-contg. 5 to 6-membered heterocycle; dotted lines means that one of them is double bond, the other being single bond; (+) is positive electric charge). The compound of formula I is obtained by reaction of an intermediate expressed by formula II with a thiol compound of formula III followed by either removing the protecting group by reduction or conducting an esterification or salt-forming reaction. The reaction is pref. made in an organic solvent such as acetone in the presence of a base such as trimethylamine under cooling.
INTRODUCTION: Observational studies suggest that different classes of antihypertensive drugs may have different effects on the occurrence of intracranial aneurysms (IA) and subarachnoid hemorrhage (SAH). However, the reported results in previous studies are inconsistent, and randomized data are absent. We performed a two-sample Mendelian randomization (MR) analysis to study the causal effects of genetically determined blood pressure (BP) and genetic proxies for antihypertensive drug classes on the risk of IA and SAH.
MATERIALS AND METHODS: Genetic instruments and outcome data were obtained from independent genome-wide association studies (GWAS) or published data, which were exclusively restricted to European ancestry. Causal relationships were identified using inverse-variance weighted MR analyses and a series of statistical sensitivity analyses. The FinnGen consortium was used for repeated analysis to verify results obtained from the above GWAS.
RESULTS: Two-sample MR analysis showed that genetically determined Systolic BP, Dystolic BP, and Pulse Pressure were related to a higher risk of IA and SAH. Based on identified single nucleotide polymorphisms (SNPs) that influence the effect of calcium channel blockers (CCB, 42 SNPs), beta-blockers (BB, 8 SNPs), angiotensin-converting enzyme inhibitors (ACEI, 2 SNPs), angiotensin receptor blockers (ARB, 1 SNPs), and thiazides (5 SNPs), genetically determined effect of CCBs was associated with a higher risk of IA (OR, 1.07 [95% CI, 1.03-1.10], p = 5.02 × 10-5) and SAH (OR, 1.06 [95% CI, 1.03-1.09], p = 1.84 × 10-3). No associations were found between other antihypertensive drugs and the risk of IA or SAH. The effect of CCBs on SAH was confirmed in FinnGenconsortium samples (OR, 1.04 [95% CI, 1.00-1.08], p = 0.042).
DISCUSSION AND CONCLUSION: This MR analysis supports the role of elevated blood pressure in the occurrence of intracranial aneurysms and subarachnoid hemorrhage. However, genetic proxies for calcium channel blockers were associated with an increased risk of intracranial aneurysms and subarachnoid hemorrhage. Further studies are required to confirm these findings and investigate the underlying mechanisms.
This is longitudinal study with the data collected from 2009-2014 from medical students and physiotherapy students at two different Scottish universities measuring attitudes towards patients with chronic low back pain and their functionality. The outcome measure used was HC-PAIRS the original 15 point Likert Scale. Data was analysed using SPSS (version 25). All data was found to be normally distributed. Descriptive statistics were presented as mean (Standard Deviation). Inferential statistics were carried out using a two-way ANOVA with year of study and discipline of degree as independent variables with post hoc analysis. A p-value of \<0.05 was considered statistically significant.
PURPOSE: To obtain a cosmetic synergistically increased in an UV light- preventing effect by compounding an UV light absorber, an UV light-diffusing agent or the UV light absorber and/or the UV light-diffusing agent with a spherical powder of an organopolysiloxane elastomer. CONSTITUTION: There are provided a cosmetic comprising a spherical powder of an organopolysiloxane elastomer itself not having an UV light-diffusing effect and an UV light-diffusing effect incorporated with one or more kinds of UV light absorbers; a cosmetic comprising a spherical powder of the organopolysiloxane elastomer incorporated with one or two kinds of the UV light-diffusing agents; and a cosmetic comprising a spherical powder of the organopolysiloxane elastomer incorporated with one or more kinds of the UV light absorbents and/or the UV light-diffusing agents. The UV light absorber is added in an amount of approximately 1-20wt.%. The UV light-diffusing agent is added in an amount of approximately 1-50wt.%. The spherical powder of the organopolysiloxane elastomer is added in an amount of approximately 1-30wt.%.  The cosmetic is improved in a sunburn-preventing effect and suability.
After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target ACT within 10% of baseline value. After protamine administration the ACT, CBC, PT/ INR, APTT, and fibrinogen, will be collected via preexisting arterial access. If ACT \>10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT \>16.6 sec/ INR \>1.6 sec will receive Prothrombin complex concentrate (Human) 15 units/kg.
Participants attend up to 3 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on 3 randomly assigned conditions (combinations of carrier and nicotine concentrations).
Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form. For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 4.0.1 or greater (commercially approved version) with DIRECTSENSE™ and Force Computation Software Module; the IntellaMap Orion mapping catheter and the IntellaNav StablePoint ablation catheter.
PURPOSE:To obtain a hydrated alginic acid film free from a dispersion of contained (effective components continuously by successively applying aqueous solutions of a soluble calcium salt, a soluble alginic acid salt and a soluble calcium salt to the surface of a substrate. CONSTITUTION:An aqueous solution of a soluble calcium salt (e.g. calcium chloride) is applied to the surface of a substrate such as a plastic film by spraying or the like. An aqueous solution of an alginate (e.g. sodium alginate) having a specified viscosity and containing a desired effective component (e.g. a medicinal component or a humectant) is further applied thereto by, e.g. casting to form a coating film of an aqueous solution of a soluble alginate. An aqueous solution of a soluble calcium salt is applied to this film to be brought into contact therewith to allow the aqueous solution of the soluble alginate to gel by the action of calcium ions. In this way, a hydrated alginic acid film suitable as an external preparation such as a pharmaceutical or cosmetic is obtained.
Stress and corticosteroid exposure are associated with changes in both the human and animal hippocampus. An extensive literature suggests that corticosteroid-induced changes in the hippocampus are, in part, mediated through increases in extracellular glutamate. In animals, agents that decrease glutamate release prevent dendritic changes in the hippocampus secondary to stress or corticosterone. We have developed a research program using patients receiving prescription corticosteroids (e.g., prednisone) to explore the effects of corticosteroids on the human hippocampus. Our research program is translational in focus, with a goal of exploring whether the reported effects of corticosteroids on the animal hippocampus are also found in humans. A current focus of our research is examining glutamate release inhibitors in patients taking corticosteroids. We have both open-label and placebo-controlled pilot data suggesting that the glutamate release inhibitor lamotrigine is associated with significant improvement in declarative memory (a measure of hippocampal performance) in this population. A definitive study examining declarative memory in corticosteroid-dependent patients receiving lamotrigine vs. placebo is proposed. Neuroimaging and mood will also be assessed.
OBJECTIVE: The aim of this study was to assess the role of elevated serum ferritin levels in the onset, pathological progression and prognosis of nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease has been rapidly increasing worldwide. Despite extensive research on the pathogenesis of nonalcoholic fatty liver disease, a lack of sufficient clinical research on the relationship between nonalcoholic fatty liver disease and serum ferritin levels remains.
METHODS: We analysed 968 patients with type 2 diabetes mellitus who underwent liver ultrasound examination and had their serum ferritin levels measured. The presence of nonalcoholic fatty liver disease and advanced liver fibrosis was determined through abdominal ultrasound examination and the nonalcoholic fatty liver disease fibrosis score.
RESULTS: Compared to that in the non-nonalcoholic fatty liver disease group, the presence of hyperferritinemia was significantly more common in the nonalcoholic fatty liver disease group (83.3 vs. 56.3%, p=0.005). When patients with nonalcoholic fatty liver disease were stratified by the nonalcoholic fatty liver disease fibrosis score, those with advanced liver fibrosis exhibited a higher prevalence of hyperferritinemia (56.3, 78.9, and 88.9% for none, simple steatosis, and advanced fibrosis, respectively; p for trend=0.002). In multivariate logistic regression, liver fibrosis was independently associated with hyperferritinemia (odds ratio [OR] 1.45; 95% confidence interval [CI] 1.18-2.02; p=0.014), and this association remained significant in male patients after adjusting for other risk factors (OR 2.66; 95% CI 1.43-5.48; p=0.026).
CONCLUSION: Identifying nonalcoholic fatty liver disease patients at a risk of developing nonalcoholic steatohepatitis and advanced fibrosis is crucial for implementing timely interventions and improving patient outcomes. This study highlights the potential utility of serum ferritin levels as a serum biomarker for identifying nonalcoholic steatohepatitis patients and those at a risk of late-stage fibrosis, particularly in male patients with nonalcoholic fatty liver disease.
Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.
The usual starting dose of ATROVENT HFA is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours.

ATROVENT HFA is a solution aerosol that does not require shaking. However, as with any other metered-dose inhaler, some coordination is required between actuating the canister and inhaling the medication.

Patients should "prime" or actuate ATROVENT HFA before using for the first time by releasing 2 test sprays into the air away from the face. In cases where the inhaler has not been used for more than 3 days, prime the inhaler again by releasing 2 test sprays into the air away from the face. Patients should avoid spraying ATROVENT HFA into their eyes.

Each inhaler provides sufficient medication for 200 actuations. The inhaler should be discarded after the labeled number of actuations has been used. The amount of medication in each actuation cannot be assured after this point, even though the canister is not completely empty.

Patients should be instructed on the proper use of their inhaler [see Patient Counseling Information (17.7)].